Multiple myeloma is a blood cancer caused by rogue plasma cells that accumulate in the bone marrow. They affect the normal production of other blood cells leading to anemia and improper functioning of the immune system. They also cause bone lesions, bone destruction and an accumulation of M-protein which can lead to kidney damage. While treatment advances have improved clinical outcomes for patients with standard-risk symptomatic disease, high-risk multiple myeloma remains an urgent area with unmet therapeutic needs.

The High-Risk Multiple Myeloma Moon Shot^® is working to rapidly adapt pre-clinical findings into treatment options for high-risk multiple myeloma. Our experts are working to predict disease progression for patients with precursor states, including MGUS and smoldering myeloma, with the ultimate goal of creating treatments that delay or stop disease progression in its tracks. The team is also exploring treatments such as immunotherapy and natural killer cells for patients with symptomatic high-risk myeloma.